基于此,中国国家癌症中心开展了一项真实世界数据的里程碑分析,探讨了HER2-low、HER2-zero对不同HR状态可切除乳腺癌预后的影响,提出HER2-low的侵袭性较HER2-zero更低,而HER2-low对预后的影响则取决于HR状态[1]。 该研究对2009年1月...
基于此,中国国家癌症中心开展了一项真实世界数据的里程碑分析,探讨了HER2-low、HER2-zero对不同HR状态可切除乳腺癌预后的影响,提出HER2-low的侵袭性较HER2-zero更低,而HER2-low对预后的影响则取决于HR状态[1]。 该研究对2009年1月至2017年9月在中国医学科学院肿瘤医院接受手术的原发性乳腺癌患者病历进行了回顾性...
本期由邵逸夫医院肿瘤外科的张力文医生为我们带来:新辅助化疗后HER2-low与HER2-zero乳腺癌的pCR、预后结局和复发模式。 张力文,医学硕士 浙江大学医学院附属邵逸夫医院肿瘤外科及乳腺疾病诊治中心主治医师
HER2-zero及HER2低表达对HR阳性乳腺癌新辅助化疗疗效影响因素分析.pdf,中文摘要 HER2-zero 及HER2 低表达对HR 阳性乳腺癌新辅助化疗疗 效影响因素分析 研究背景: 乳腺癌是全球范围内女性发病率第一的恶性肿瘤,随着诊断和治 疗方法的不断完善,患者的预后得到了显著改善。
A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
When comparing the proportion of high RS between the two groups, the HER2-zero group had a high RS rate of 12.4% (117 out of 944), while the HER2-low group had a high RS rate of 17.0% (230 out of 1351) (p=0.002). The HER2 score identified by qRT-PCR was 8.912 in the HER2-...
Of these, 944 (41.1%) patients were assigned to the HER2-zero group, while 1351 (58.9%) patients were assigned to the HER2-low group. The average Recurrence Score (RS) was found to be 17.802 in the HER2-zero breast cancer group and 18.503 in the HER2-low group, respectively (p-value...
In hormone receptor (HR)-positive subgroup, SUVmax and TLR were significantly higher in HER2-low than in HER2-zero (P = 0.045 and 0.03, respectively). But in HR-negative subgroup, there was no significant metabolic difference between HER2-low and HER2-zero (All P > 0.05). The ...
Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.
Breast cancer HER2 expression has been redefined using a three-tiered system, with HER2-zero cancers considered ineligible for HER2-targeted therapy, HER2-low cancers considered candidates for novel HER2-targeted drugs, and HER2-positive cancers treated with traditional HER2-targeted medications.OBJECTIVE...